Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 12/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | VHL | P40337 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16517650 | 0.89 | MAP3K14 (0.42) | MAP3K14SCN9AVHLROCK1 | |
| SCHEMBL18673361 | 0.86 | MAP3K14 (0.43) | MAP3K14SCN9AELANE | |
| SCHEMBL18673546 | 0.86 | MAP3K14 (0.44) | MAP3K14SCN9AELANE | |
| SCHEMBL18888035 | 0.85 | MAP3K14 (0.43) | MAP3K14SCN9AELANE | |
| SCHEMBL18673406 | 0.80 | MAP3K14 (0.54) | MAP3K14SCN9AELANEKDM4EALDH1A1 | |
| SCHEMBL18673449 | 0.79 | MAP3K14 (0.62) | MAP3K14SCN9AELANE | |
| SCHEMBL16517705 | 0.78 | MAP3K14 (0.43) | MAP3K14SCN9A | |
| SCHEMBL16517126 | 0.77 | MAP3K14 (0.76) | MAP3K14 | |
| SCHEMBL16516957 | 0.77 | MAP3K14 (0.76) | MAP3K14 | |
| SCHEMBL16532434 | 0.76 | MAP3K14 (0.45) | MAP3K14SCN9AKDM4ECYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | MAP3K14 514/4885SCN9A 760/4885ELANE 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.